All-trans retinoic acid and late relapses in acute promyelocytic leukemia: very
long-term follow-up of the North American Intergroup Study I0129.
Author(s): Douer D(1), Zickl LN, Schiffer CA, Appelbaum FR, Feusner JH, Shepherd L, Willman
CL, Bloomfield CD, Paietta E, Gallagher RE, Park JH, Rowe JM, Wiernik PH, Tallman
MS.
Affiliation(s): Author information:
(1)Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center,
Weill Cornell Medical College, New York, NY, USA. douer@mskcc.org
Publication date & source: 2013, Leuk Res. , 37(7):795-801
We report a long-term follow-up (median 11.8 years) of the First North American
Intergroup Study. 379 patients were randomized to induction with ATRA or to
chemotherapy. All complete responders (CR) received consolidation chemotherapy,
then randomized to 1 year ATRA or observation. 245 patients received ATRA
sometime during the study: 195 (80%) achieved a CR. Nine (4.6%) relapsed late (>3
years from CR), the last occurred after 4.6 years; 7 of them were still alive
after 5.5-15 years. In APL patients, late relapses are uncommon, and those who
sustain CR >5 years can be considered cured.
|